Docetaxel impurity G
Docetaxal
CAS: 125354-16-7
Molecular Formula: C45H55NO15
Docetaxel impurity G - Names and Identifiers
Docetaxel impurity G - Physico-chemical Properties
| Molecular Formula | C45H55NO15 |
| Molar Mass | 849.93 |
| Density | 1.36±0.1 g/cm3(Predicted) |
| Melting Point | 201-203 °C(Solv: methanol (67-56-1)) |
| Boling Point | 901.4±65.0 °C(Predicted) |
| Solubility | Chloroform (Slightly), Methanol (Slightly) |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | 11.20±0.46(Predicted) |
| Storage Condition | 2-8°C |
Docetaxel impurity G - Reference
| Reference Show more | 1. Zheng Yu, Li Xiaofang, Wu Chaoqun, et al. Formulation optimization and quality evaluation of docetaxel and gambogic acid albumin nanoparticles [J]. Chinese Journal of Experimental prescriptions, 2019, 025(016):104-110. 2. Gang Chen. Mechanism of Rictor/Fos gene mediated by MicroRNA-155 in promoting cisplatin resistance of gastric cancer cells [J]. Lanzhou University, 2020. |
Docetaxel impurity G - Reference Information
| pharmacological action | docetaxel is a paclitaxel anti-tumor drug, which plays an anti-tumor role by interfering with the microtubule network necessary for cell mitosis and interphase cell function. Docetaxel can bind to free tubulin, promote tubulin assembly into stable microtubules, and inhibit its depolymerization, resulting in the loss of normal function of microtubule bundle production and microtubule fixation, thereby inhibiting cell mitosis. The combination of docetaxel and microtubules does not change the number of fibrils, which is different from most spindle toxic drugs currently used in clinical practice. |
| indications | for the treatment of advanced breast cancer and non-small cell lung cancer. It is also used to treat head and neck cancer, small cell lung cancer, gastric cancer, ovarian cancer and other tumors. |
| drug interaction | 1. when combined with cisplatin, the risk of neuropathy increases. 2. itraconazole can inhibit the metabolism of this drug and increase the toxicity of this drug. 3. In vitro studies have shown that CYP3A4 inhibitors may interfere with the metabolism of this drug. When this drug is combined with such drugs (such as ketoconazole, erythromycin, cyclosporine, etc.), special caution should be taken. 4. when combined with topotecan, the clearance rate of topotecan can be reduced by 50% after 3 days of treatment. When the two are used together, it is recommended to give this medicine on the 1st and topotecan on the 1st to 4th. 5. Inoculation of live vaccine during medication will increase the risk of infection of live vaccine, so live vaccine cannot be vaccinated during medication. Chemotherapy is stopped for at least 3 months before live vaccination. |
| action and use | the same as paclitaxel, it has good curative effect on non-small cell lung cancer and breast cancer, and can also be used for head and neck cancer and ovarian cancer. |
| usage and dosage | the recommended dose is 75 mg/m2 every 3 weeks for intravenous drip for more than 1 hour. Where the white blood cell count is less than 1.5 × 109/L, pregnant women, lactating women and children are prohibited. |
| adverse reactions | 1. bone marrow suppression: neutropenia is the most common side effect and is usually more serious (less than 500/mm3). Reversible and not accumulated. 2. anaphylaxis: severe anaphylaxis may occur in some cases, characterized by hypotension and bronchospasm, which require interruption of treatment. The patient returned to normal after stopping the instillation and immediate treatment. Some cases may also have mild allergic reactions, such as blushing, erythema with or without itching, chest tightness, back pain, dyspnea, drug fever or chills. 3. the skin reaction is often manifested as erythema, mainly in the hands and feet, and can also occur in the arm, face and chest local rash, sometimes accompanied by itching. The rash usually occurs within 1 week after the instillation of docetaxel and can recover before the next instillation. Severe symptoms such as peeling after rash are rare. Finger (toe) nail lesions may occur, characterized by pigmentation or fading, and sometimes pain and nail loss. 4. Fluid retention includes edema. There are also very few reports of pleural effusion, ascites, pericardial effusion, increased capillary permeability and weight gain. After 4 cycles of treatment or a cumulative dose of 400mg/m2, fluid retention in the lower limbs may develop to systemic edema, and weight gain of 3kg or more. After stopping docetaxel therapy, fluid retention gradually disappeared. In order to reduce fluid retention, patients should be given prophylactic use of glucocorticoids. 5. may occur nausea, vomiting or diarrhea and other gastrointestinal reactions. 6. Neurotoxicity has been reported in clinical trials. 7. Cardiovascular side effects such as hypotension, sinus tachycardia, palpitations, pulmonary edema and hypertension may occur. 8. Other side effects include alopecia, weakness, mucositis, arthralgia and muscle pain, hypotension and injection site reaction. 9. patients with normal liver function also have elevated aminotransferase and bilirubin during treatment, and its relationship with docetaxel is not clear. |
Last Update：2024-04-09 21:04:16
Supplier List
Spot supply
Product Name: Docetaxal Request for quotationCAS: 125354-16-7
Tel: +86-17551318830
Email: r@reformchem.com
Mobile: +86-17551318830
QQ: 3785839865
Spot supply
Product Name: Docetaxel Impurity 7(Docetaxel EP Impurity G) Visit Supplier Webpage Request for quotationCAS: 125354-16-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Docetaxal Visit Supplier Webpage Request for quotationCAS: 125354-16-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Docetaxal Request for quotationCAS: 125354-16-7
Tel: +86-17551318830
Email: r@reformchem.com
Mobile: +86-17551318830
QQ: 3785839865
Spot supply
Product Name: Docetaxel Impurity 7(Docetaxel EP Impurity G) Visit Supplier Webpage Request for quotationCAS: 125354-16-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Docetaxal Visit Supplier Webpage Request for quotationCAS: 125354-16-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History